Cite
MLA Citation
J. Shen et al.. “FRI0322 Rationale for the atacicept dose for a phase iii study in patients with highly active and auto-antibody positive sle.” Annals of the rheumatic diseases, vol. 77, n.d., p. 697. http://access.bl.uk/ark:/81055/vdc_100144718389.0x000042